Enhancement of Alkylating Agent Activity by SR-4233 in the FSaIIC Muraine Fibrosarcoma
The DOI matches its Crossref record.
Abstract
BACKGROUND: The most commonly used antineoplastic drugs are more cytotoxic toward normally oxygenated tumor cells than toward hypoxic tumor cells. PURPOSE AND METHODS: To examine the ability of SR-4233, a new cytotoxic agent, to overcome the resistance of hypoxic tumor cells to antitumor alkylating agents, we tested the cytotoxic effect of SR-4233 alone and in combination with varying doses of cisplatin (CDDP), cyclophosphamide (CPM), carmustine (BCNU), or melphalan (L-PAM) on tumor cells and bone marrow cells isolated from C3H/FeJ mice bearing the FSaIIC fibrosarcoma. RESULTS: When SR-4233 alone was given, tumor cell killing was limited. When SR-4233 was administered just before single-dose treatment with CDDP, CPM, BCNU, or L-PAM, however, marked dose enhancement leading to increased cytotoxic effects on tumor cells and on bone marrow cells was observed. Similar experiments with tumor cell subpopulations, selected by Hoechst 33342 dye diffusion, confirmed that while cytotoxicity to both bright (oxygenated) and dim (hypoxic) cells was increased by combining each alkylating agent with SR-4233, the enhancement of the effect was relatively greater in the subpopulation of dim cells. The delay in the growth of tumors in animals treated with the combination of SR-4233 and CDDP, CPM, or L-PAM was 1.6-fold to 5.3-fold greater than that in animals treated with each alkylating agent alone. CONCLUSION: Our results suggest that SR-4233 may have the potential to improve the clinical efficacy of commonly used antitumor alkylating agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia
Parmar, K., Mauch, P., Vergilio, J.-A., Sackstein, R., & Down, J. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701152104 · Cited by 867
Teicher, B. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689633 · Cited by 563
Self-citationSR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
Brown, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.220 · Cited by 366
von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1351 · Cited by 285
Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
Salem, A., Asselin, M.-C., Reymen, B., Jackson, A., Lambin, P., West, C. M. L., O’Connor, J. P. B., & Faivre-Finn, C. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx160 · Cited by 266
Metadata
- Authors
- Holden, S. A., Teicher, B. A., Ara, G., Herman, T. S., & Coleman, C. N.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1992-02-05
- Volume
- 84
- Issue
- 3
- Pages
- 187-193
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2116004702
- Cited by
- 42
- References
- 0
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancement of Alkylating Agent Activity by SR-4233 in the FSaIIC Muraine Fibrosarcoma. https://app.cochat.ai/papers/10.1093/jnci/84.3.187
- The paper
- Holden, S. A., Teicher, B. A., Ara, G., Herman, T. S., & Coleman, C. N. (1992). Enhancement of Alkylating Agent Activity by SR-4233 in the FSaIIC Muraine Fibrosarcoma. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/84.3.187
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.